Sayegh M H, Perico N, Gallon L, Imberti O, Hancock W W, Remuzzi G, Carpenter C B
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Transplantation. 1994 Jul 27;58(2):125-32.
We have recently shown that a single intrathymic injection of synthetic 25mer peptides, representing full sequences of the hypervariable domain of RT1.BuB (4 peptides) and RT1.Du beta (4 peptides) WF class II MHC molecules, 48 hr before transplantation induces donor-specific unresponsiveness to WF rat renal allografts in adult LEW recipients. The induction of unresponsiveness was abrogated by the recipient's thymectomy within the first week after intrathymic injection. Peripheral T cells of long-term survivors exhibited antigen-specific hyporesponsiveness in the LEW x WF MLR. Studies on the mechanisms of induction of acquired thymic unresponsiveness to alloantigen in vivo and in vitro are now reported. First, since we have previously demonstrated in LEW responders that only 4 of the 8 synthetic 25mer peptides, 2 RT1.Du beta and 2 RT1.Bu beta sequences, were immunogenic in vitro and in vivo, we compared the tolerogenicity of the immunogenic versus the nonimmunogenic peptides. While LEW rats intrathymically injected with the nonimmunogenic peptides acutely rejected their renal allografts within 6-10 days, animals injected with the immunogenic peptides did not reject their grafts and are surviving > 100 days with normal allograft function. In vitro studies established that peripheral T cells from intrathymically tolerized animals exhibited antigen-specific hyporesponsiveness in the LEW x WF MLR starting as early as 1 week posttransplant. Immunohistological evaluation of renal allografts from intrathymically tolerized animals 1 week postengraftment showed marked reduction in mononuclear cell infiltrates with no evidence of tubulitis, and marked reduction in intragraft staining for activation and inflammatory cytokines and alloantibodies, as compared with acutely rejecting controls. Systemic administration of 1000 U of rIL-2 daily for 5 days starting on the day of transplantation abrogated the tolerogenic effect of intrathymic MHC allopeptides. Injection of 100 micrograms of a single immunogenic peptide, RT1.Du beta 2 (residues 20-44), into the thymus of responder LEW rats 48 hrs before immunization with RT1.Du beta 2 effected significant reduction of in vitro proliferation of primed lymphocytes to RT1.Du beta 2, an effect that was abrogated by addition of rIL-2 in vitro. In contrast, thymectomy beyond 2 weeks and administration of rIL-2 at 4-6 weeks after transplantation failed to cause rejection. These observations indicate that thymic recognition of immunodominant class II MHC allopeptides leads to peripheral T cell anergy that mediates the induction phase of systemic unresponsiveness to renal allografts. The maintenance phase appears to be mediated by dense anergy or clonal deletion.(ABSTRACT TRUNCATED AT 400 WORDS)
我们最近发现,在移植前48小时向成年LEW受体胸腺内单次注射合成的25聚体肽,这些肽代表RT1.BuB(4种肽)和RT1.Duβ(4种肽)WF II类MHC分子高变区的完整序列,可诱导其对WF大鼠肾同种异体移植产生供体特异性无反应性。胸腺内注射后的第一周内,受体胸腺切除可消除无反应性的诱导。长期存活者的外周T细胞在LEW×WF混合淋巴细胞反应中表现出抗原特异性低反应性。现将关于体内和体外诱导获得性胸腺对同种异体抗原无反应性机制的研究报告如下。首先,由于我们之前在LEW反应者中证明,8种合成25聚体肽中只有4种,即2种RT1.Duβ和2种RT1.Buβ序列,在体内外具有免疫原性,我们比较了免疫原性肽与非免疫原性肽的致耐受性。胸腺内注射非免疫原性肽的LEW大鼠在6 - 10天内急性排斥其肾同种异体移植,而注射免疫原性肽的动物未排斥其移植肾,且移植肾功能正常存活超过100天。体外研究表明,胸腺内诱导耐受动物的外周T细胞最早在移植后1周开始在LEW×WF混合淋巴细胞反应中表现出抗原特异性低反应性。对胸腺内诱导耐受动物移植后1周的肾同种异体移植进行免疫组织学评估显示,与急性排斥对照组相比,单核细胞浸润明显减少,无肾小管炎证据,移植内激活、炎性细胞因子和同种异体抗体的染色明显减少。从移植当天开始,连续5天每天全身给予1000 U的重组人白细胞介素-2可消除胸腺内MHC同种异体肽的致耐受作用。在对RT1.Duβ2进行免疫前48小时,向反应性LEW大鼠胸腺内注射100μg单一免疫原性肽RT1.Duβ2(第20 - 44位氨基酸残基),可显著降低致敏淋巴细胞对RT1.Duβ2的体外增殖,体外添加重组人白细胞介素-2可消除该作用。相反,移植后2周以上进行胸腺切除以及在移植后4 - 6周给予重组人白细胞介素-2未能导致排斥反应。这些观察结果表明,胸腺对免疫显性II类MHC同种异体肽的识别导致外周T细胞无反应性,介导了对肾同种异体移植全身无反应性的诱导阶段。维持阶段似乎由密集无反应性或克隆清除介导。(摘要截断于400字)